Home
Early trials for AstraZeneca's COVID-19 vaccine show promise.

Early trials for AstraZeneca's COVID-19 vaccine show promise.

Marble
| 5 min

Pharmaceutical giant, AstraZeneca has collaborated with Oxford University creating a possible COVID-19 vaccine. Their most recent human trials, run by the National Institutes of Health, have shown very promising results. Although these trials are in their early stages, researchers believe the AstraZeneca vaccine can produce enough antibodies along with killer T-cells to protect the body for two months. The sizeable amount of positive responses to the potential vaccine has brought fresh hope to creating an effective vaccine for coronavirus. So far, the side effects of the vaccine are mild, and most commonly headache and fatigue. Upon completion, AstraZeneca plans to expedite their manufacturing of their coronavirus vaccine with a goal of distributing 2 billion doses.  AstraZeneca and Oxford’s promising COVID-19 vaccine is one of over a hundred currently being developed worldwide.

Bankruptcy
|